Stock Ratings / Health Care / ORIC / financials

AKTS (41) CYRX (43) KURA (32) ANRO (35) ⌘ Pro Terminal →

Oric Pharmaceuticals Inc. (ORIC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is Oric Pharmaceuticals Inc. (ORIC)?

In FY 2025 (10-K), ORIC converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$9.24 +2.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.27

Oric Pharmaceuticals Inc. (ORIC) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $931.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ORIC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ORIC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $9.24 (+2.78% 1D, market cap $931.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ORIC ranks #871 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ORIC compare to AKTS and CYRX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ORIC carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -33.4%. By comparison, AKTS (Aktis Oncology Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $937.2M) and CYRX (CryoPort Inc.) posts a D- grade (43/100 RQD, P/E 11.8x, ROIC -11.5%, cap $926.4M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ORIC?

▼

Per ORIC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001796280), Oric Pharmaceuticals Inc. generated $0 in revenue, -$129.5M in net income, and -$111.7M in free cash flow against $408.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.27 (+0.31%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ORIC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (29/100 Composite)

🔍 WHY ORIC SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$11.81+7.7% Next Q

Q2 (-2Q)

Grade E$12.72-29.6% Next Q

Q3 (-1Q)

Grade E$8.95+3.2% Next Q

Current

Grade E$9.24-9.8% Hist 90D α

Trajectory: E (37) → E (29)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ORIC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ORIC currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.36) and Max Pain ($9.70) forces dealer call-delta covering toward $15.41.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ORIC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ORIC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 29%NO 71%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ORIC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-3.6%	-$129.5M	-$111.7M	-33.4%
FY 2024	$4.00B	52%	-3.6%	-$127.8M	-$113.8M	-45%
FY 2023	$4.00B	52%	-2.8%	-$100.7M	-$85.7M	-33.4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ORIC)

✓Walkthrough of ORIC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ORIC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.05%▼ SUPPORT BREAKDOWN

2026-11-02O $9.30H $9.30L $8.99C $9.24VOL 1.05M

RES: $14.23SUP: $11.10SMA50: $12.36SMA200: $11.13

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ORIC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ORIC Butterfly Map → + Track ORIC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ORIC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ORIC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ORIC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ORIC)

Health Care Rank #871 of 1016 ⚔️ AKTS vs ORIC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ORIC vs. AKTS, CYRX, KURA, ANRO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Oric Pharmaceuticals Inc. (ORIC) ranks #871 by composite RQD confidence (29/100, grade E) and #371 by equity capitalization ($931.8M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. CYRX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ORIC at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ORIC ACTIVE Oric Pharmaceuticals Inc.	E	29/100	—	—	-33.4%	+2.78%	$931.8M	Benchmark Subject
AKTS Aktis Oncology Inc.	D-	41/100	—	—	—	-5.46%	$937.2M	/akts-vs-oric →
CYRX CryoPort Inc.	D-	43/100	11.8x	47.1%	-11.5%	-5.47%	$926.4M	/cyrx-vs-oric →
KURA Kura Oncology Inc.	E	32/100	—	—	-35.0%	-2.84%	$939.4M	/kura-vs-oric →
ANRO Alto Neuroscience Inc.	D-	35/100	—	—	-35.0%	-3.71%	$921.0M	/anro-vs-oric →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001796280

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Oric Pharmaceuticals Inc. (ORIC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$129.5M, operating cash flow of -$111.0M, and free cash flow of -$111.7M (+1.9% YoY). On the balance sheet, ORIC closed FY2025 with $408.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$129.5M	-$111.0M	-$111.7M	$408.9M	—
FY2024 (FY)	2024-12-31	$0	-$127.8M	-$112.7M	-$113.8M	$274.1M	—
FY2023 (FY)	2023-12-31	$0	-$100.7M	-$85.7M	-$85.7M	—	—

3. ORIC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ORIC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ORIC compare to AKTS and CYRX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ORIC?

Where is ORIC trading relative to its 50-day, 200-day, and 52-week technical levels?

ORIC last traded at $9.24 (+2.78% on volume of 2,441,686 shares), positioning the stock -25.24% below its 50-day simple moving average ($12.36) and -16.98% below its 200-day simple moving average ($11.13). Across its 52-week range of $7.23 to $14.68, ORIC sits at the 27.0% percentile with a 14-day RSI of 31.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($8.08 to $10.40).

ORIC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Oric Pharmaceuticals Inc. (ORIC)?

In FY 2025 (10-K), ORIC converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: ORIC RQD Cockpit ORIC 12M Forecast ORIC Earnings & Move ORIC Dividends & DRIP ORIC Insiders & 13F ORIC Whale Options ORIC Profit Sankey ORIC News & Why

ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ORIC — Oric Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:31:44Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ORIC scores 29 out of 100, graded E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 7 / 20. Per the Roarable RQD rating, this reflects ROIC of -33.4% and FCF yield of -11.99%. For a prospective investor, negative returns on invested capital and negative free cash flow indicate that the business is currently consuming capital rather than generating it. Upside from this pillar depends on a future shift to cash generation, which the source data does not establish.
Whale 13F Flow: 3 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The low score suggests limited institutional support in the rating's framework. Institutional holder detail is not available in the source data, so the drivers behind this score cannot be verified here.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score is consistent with the CFO Form 4 sale reported in the news wire (see Recent Catalysts). Insider selling is one input among many and does not by itself establish a directional outcome.
Macro Regime Fit: 6 / 20. Per the Roarable RQD rating, beta of 1.0 and sector sensitivity drive this score. A beta of 1.0 implies market-like volatility relative to the broader market; the score indicates limited regime-based support.
Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z of 2.5, Piotroski F of 2/9, and Debt/Equity of 0.5 drive this score. The Piotroski reading is weak, and the Altman figure sits in the range the rating treats as a moderate-risk area; the Debt/Equity figure is comparatively contained.

Taken together, the rating frames ORIC as carrying elevated forensic and fundamental risk with weak institutional and insider signals. A prospective investor should weigh the cash-burn profile heavily against any upside thesis that depends on future clinical or commercial milestones, none of which are quantified in the source data.

Business

Oric Pharmaceuticals Inc. is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M across the FY 2023–FY 2025 periods shown in the SEC financials. Market capitalization is $0.9B per the profile.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-143.0M	$-129.5M	N/A	$-111.7M	$45.7M	N/A
FY 2024	$0.0M	$-142.9M	$-127.8M	N/A	$-113.8M	$59.4M	N/A
FY 2023	$0.0M	$-110.8M	$-100.7M	N/A	$-85.7M	N/A	N/A

Per the SEC financials, reported revenue is $0.0M in each period and operating income and net income are negative throughout. Gross, operating, and net margins are each recorded as 0% in the market data. Per the Roarable RQD rating, ROIC is -33.4% and the Altman Z-Score is 2.5, while the Piotroski F-Score is 2/9. Reported cash declined from $59.4M in FY 2024 to $45.7M in FY 2025, and debt is not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news wire, the feed includes several market-wire and catalyst items:

A Yahoo Finance item on ORIC market action and institutional positioning (YELLOW, MARKET WIRE).
A Yahoo Finance item describing a modest fair value lift tied to trial catalyst optimism (YELLOW, MARKET WIRE).
A TradingView item reporting a Wedbush Outperform maintenance with a $14 price target (GREEN, CATALYST).
A MarketBeat item reporting shares up 8.5% on an analyst upgrade (GREEN, CATALYST).
A GuruFocus item reporting that the CFO sold 14,000 shares (YELLOW, MARKET WIRE).
A TradingView item reporting a Stifel Buy maintenance with an $18 price target (YELLOW, MARKET WIRE).

Risk watch items include the CFO share sale and the mixed signal set (two GREEN catalyst items against several YELLOW market-wire items). The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations for ORIC. Within the stated sector (Health Care) and industry (Biotechnology: Pharmaceutical Preparations), a prospective investor would ordinarily watch for 2nd-order bottlenecks in clinical, manufacturing, and partnering relationships; the source data does not confirm any of these for ORIC.

Analyst View & Smart Money Ownership

Per the analyst data and holders sections, no analyst or holder data is available in the source data. Analyst price-target references appear only in the news wire: Wedbush (Outperform, $14 price target) and Stifel (Buy, $18 price target). Consensus rating, count of analysts, and 13F, Form 4, or Congressional holder detail are not available in source data beyond the CFO share-sale headline in the news wire.

Open Questions

What are ORIC's products, clinical programs, or commercial partnerships, and what are their timelines?
What is the company's current debt balance, given Debt is recorded as N/A across all periods?
What drives the reported cash decline and what is the runway at the FY 2025 burn rate?
What is the basis for the analyst price targets referenced in the news wire, and is there a consensus?
What institutional and insider holdings exist, given the holders section is empty?

ORIC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Oric Pharmaceuticals Inc. (ORIC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ORIC Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 8h ago

ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history

Yahoo Finance Singapore report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 11h ago

ORIC Pharmaceuticals (ORIC) Stock Sees Modest Fair Value Lift On Trial Catalyst Optimism

Yahoo Finance report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 14h ago

Wedbush maintains Outperform rating on ORIC Pharmaceuticals, $14 price target

TradingView report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 17h ago

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Climb 8.5% on Analyst Upgrade

MarketBeat report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 20h ago

ORIC Pharmaceuticals (ORIC) CFO Dominic Piscitelli Sells 14,000 Shares

GuruFocus report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 23h ago

Stifel maintains Buy rating on ORIC Pharmaceuticals, $18 price target

TradingView report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 13.7% - What's Next?

MarketBeat report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

ORIC Stock In Focus As New Lung Cancer Trial Data Heads To ESMO 2026

Yahoo Finance report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ORIC Bull vs. Bear Conversation Board — What's Your Call at $9.24?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ORIC 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $7.91 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ORIC (E • RQD 29/100) a Buy at $8.99?

Welcome to the ORIC (Oric Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.19 (-20.0%)

Spot @ $8.99

Pump the brakes on ORIC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ORIC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Oric Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $10.61 (+18.0%)

Spot @ $8.99

ORIC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ORIC, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.99 (52-wk range $7.23 - $14.68), any beat on forward guidance forces shorts and underweight funds to chase.